公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
公司地址 One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
電話號碼 +1 732 524-0400
傳真號碼 --
公司網頁 https://www.jnj.com
員工數量 138200
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. John C. Reed,M.D.,PhD Executive Vice President, Innovative Medicine, R&D 美元 1.22M 11/02/2026
Mr. Joaquin Duato Chairman of the Board and Chief Executive Officer 美元 1.60M 11/03/2026
Mr. Joseph J. Wolk, C.P.A. Executive Vice President and Chief Financial Officer 美元 1.24M 11/02/2026
Mr. James D. Swanson Executive Vice President and Chief Information Officer -- 11/02/2026
Ms. Kathryn E. Wengel Executive Vice President and Chief Technical Operations and Risk Officer -- 11/02/2026
Mr. Robert J. Decker, Jr Controller and Chief Accounting Officer -- 11/02/2026
Ms. Vanessa Broadhurst Executive Vice President, Global Corporate Affairs -- 11/02/2026
Ms. Elizabeth Forminard Executive Vice President and Chief Legal Officer -- 11/02/2026
Mr. Timothy Schmid Executive Vice President and Worldwide Chairman, MedTech 美元 942.31K 11/02/2026
Ms. Kristen Mulholland Executive Vice President and Chief Human Resources Officer -- 11/02/2026
Mr. Tom Cavanaugh Executive Vice President and Worldwide Chairman, Innovative Medicine -- 04/08/2026
 
董事會成員
董事會 職務 更新日期
Mr. John G. Morikis Independent Director 11/03/2026
Ms. Marillyn A. Hewson Lead Independent Director 11/03/2026
Dr. Paula A. Johnson, M.D.,M.P.H. Independent Director 11/03/2026
Mr. Hubert Joly Independent Director 11/03/2026
Mr. Daniel Eduardo Pinto Independent Director 11/03/2026
Dr. Mary C. Beckerle, PhD Independent Director 11/03/2026
Dr. Mark B. McClellan, M.D.,PhD Independent Director 11/03/2026
Mr. Joaquin Duato Chairman of the Board and Chief Executive Officer 11/03/2026
Dr. Jennifer A. Doudna, PhD Independent Director 11/03/2026
Mr. Eugene A. Woods Independent Director 11/03/2026
Dr. Nadja Y. West, M.D. Independent Director 11/03/2026
Mr. Mark A. Weinberger Independent Director 11/03/2026
 
所屬ETF (更新日期: 19/09/2026 02:28)
代號 名稱 佔比% ▼ 持有日期
JDOCJPMorgan Healthcare Leaders ETF0.0001%31/07/2026
CSHPiShares Dynamic Short-Term Active ETF0.0001%30/07/2026
PLGIPL Growth and Income ETF0.0001%31/07/2026
GEWCambria Global EW ETF0.0001%31/07/2026
SCLZSwan Enhanced Dividend Income ETF0.0001%31/08/2026
JOYTJPMorgan Equity And Options Total Rt ETF0.0001%31/07/2026
KNGZFirstTrust S&P500 DvrsDiv AristocratsETF0.0001%30/07/2026
TOPCiShares S&P 500 3% Capped ETF0.0001%31/07/2026
NTSDWisdomTree Efficient U.S. Pls Intl Eq Fd0.0001%31/07/2026
PEPSParametric Equity Plus ETF0.0001%31/07/2026
VUSVirtus U.S. Dividend ETF0.0001%31/07/2026
HIDVAB US High Dividend ETF0.0001%31/07/2026
BDVGiMGP Berkshire Dividend Growth ETF0.0001%30/06/2026
ENDWCambria Endowment Style ETF0.00005%31/07/2026
JUSAJPMorgan ActiveBuilders US Lg Cp Eq ETF0.00005%31/08/2023
AVIEAvantis Inflation Focused Equity ETF0.00005%31/07/2026
DEUSXtrackers Russell US Multifactor ETF0.00005%30/07/2026
INROiShares U.S. Industry Rotation Act ETF0.00005%31/07/2026
FFLVFidelity Fundamental Large Cap Value ETF0.00005%31/07/2026
HEQQJPMorgan Nasdaq Hdg Eq Ldrd Overlay ETF0.00005%31/07/2026
  1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19    20    21    22   23    24    25    26    27  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.